Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$886.47 USD

886.47
1,507,253

+0.92 (0.10%)

Updated Oct 4, 2024 03:55 PM ET

After-Market: $885.55 -0.92 (-0.10%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

State of California Sues Insulin Makers for Unfair Practices

The lawsuit aims to curb the skyrocketing cost of insulin charged by insulin manufacturers and pharmacy benefit managers companies. The State also seeks to recover some monetary compensation.

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Eli Lilly (LLY) closed at $359.12 in the latest trading session, marking a -0.36% move from the prior day.

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe

Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

Campbell Soup and Eli Lilly have been highlighted as Zacks Bull and Bear of the Day

Campbell Soup and Eli Lilly have been highlighted as Zacks Bull and Bear of the Day.

Kevin Cook headshot

Bear of the Day: Eli Lilly (LLY)

Guidance for this year drags down analyst EPS estimates by nearly 10% to just 9% growth

Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's

FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

Eli Lilly (LLY) closed at $362.94 in the latest trading session, marking a +1.12% move from the prior day.

Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?

According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Eli Lilly (LLY) Stock Moves -0.23%: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $364.99, marking a -0.23% move from the previous day.

SNY or LLY: Which Is the Better Value Stock Right Now?

SNY vs. LLY: Which Stock Is the Better Value Option?

Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More

Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $365.22, marking a +0.09% move from the previous day.

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $364.88, marking a -0.82% move from the previous day.

ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly

ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.

The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly

United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.

Roche (RHHBY) Actemra Gets FDA Nod for Adults With COVID-19

Roche (RHHBY) obtains FDA approval for Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients. The drug was earlier granted an EUA.

Ekta Bagri headshot

3 Drug Stocks Most Wall Street Analysts Are Bullish About

Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?

Based on the average brokerage recommendation (ABR), Lilly (LLY) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Eli Lilly (LLY) Stock Moves -0.58%: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $357.78, marking a -0.58% move from the previous day.

Shaun Pruitt headshot

Time to Buy Eli Lilly (LLY) and AbbVie (ABBV) Stock for 2023?

AbbVie's valuation, in particular, makes it a potentially strong candidate for 2023, while Eli Lilly's growth could support its stock next year.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More

Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study.

SNY vs. LLY: Which Stock Is the Better Value Option?

SNY vs. LLY: Which Stock Is the Better Value Option?